Fortunately, the introduction of interleukin-1 (IL-1) blockers in the present decade constituted a paradigm shift towards the targeted therapy of colchicine-resistant glucocorticoid-dependent recurrent pericarditis [33,34,35,36,37,38,39,40,41,42,43]. Here, IL1A is linked to pericarditis.